CN1593505A - Quick acting and heart resurrecting oral disintegrating tablet and its preparation process - Google Patents
Quick acting and heart resurrecting oral disintegrating tablet and its preparation process Download PDFInfo
- Publication number
- CN1593505A CN1593505A CN 200410019985 CN200410019985A CN1593505A CN 1593505 A CN1593505 A CN 1593505A CN 200410019985 CN200410019985 CN 200410019985 CN 200410019985 A CN200410019985 A CN 200410019985A CN 1593505 A CN1593505 A CN 1593505A
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- cavity disintegration
- disintegration tablet
- medicinal ingredient
- borneolum syntheticum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 claims abstract description 102
- 239000004615 ingredient Substances 0.000 claims abstract description 57
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 56
- 210000000214 mouth Anatomy 0.000 claims abstract description 45
- 239000003094 microcapsule Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 239000000945 filler Substances 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims abstract description 6
- 239000006185 dispersion Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 208000019622 heart disease Diseases 0.000 claims description 24
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 24
- 239000004005 microsphere Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 16
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 14
- 229940013618 stevioside Drugs 0.000 claims description 14
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 14
- 235000019202 steviosides Nutrition 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000012567 medical material Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000000741 silica gel Substances 0.000 claims description 12
- 229910002027 silica gel Inorganic materials 0.000 claims description 12
- 239000007962 solid dispersion Substances 0.000 claims description 12
- 208000035126 Facies Diseases 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical group O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 108010011485 Aspartame Proteins 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000000605 aspartame Substances 0.000 claims description 8
- 235000010357 aspartame Nutrition 0.000 claims description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 8
- 229960003438 aspartame Drugs 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000011734 sodium Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000003825 pressing Methods 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- -1 Oleum menthae Chemical compound 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000003809 water extraction Methods 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 229940126678 chinese medicines Drugs 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- 238000012695 Interfacial polymerization Methods 0.000 claims description 2
- 239000008118 PEG 6000 Substances 0.000 claims description 2
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 238000005354 coacervation Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004531 microgranule Substances 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 208000019505 Deglutition disease Diseases 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract 3
- 206010010071 Coma Diseases 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 238000004821 distillation Methods 0.000 description 10
- 230000000857 drug effect Effects 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000028399 Critical Illness Diseases 0.000 description 3
- 208000010513 Stupor Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000009982 suxiao jiuxinwan Substances 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000008398 formation water Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
速效救心口崩片及其制备方法，属于一种含易升华药用成分的中药口崩型制剂及其制备技术。它解决了速效救心药物，在当前生产和储存中，有效成分——冰片易升华、使药效含量不稳定及昏迷、重症病人服药不便的问题。本发明应用现代化包裹技术，将冰片制备成固体微囊(球)或分散体，与川芎、矫味剂混合，再与填充剂、崩解剂、润滑剂、助流剂均混、过筛、压片制得口崩片。该制剂服用方便、不需要在口腔内含水就能充分崩解，崩解时间在10～50秒内完成，并可瞬时高效释药、起效快、达峰早，所以该口崩片，特别适合于部分吞咽困难或昏迷病人用药，其疗效显著。本发明不仅制备工艺简捷、并且优化了生产环境，既有经济效益，又有社会效益。Quick-acting Jiuxin orally disintegrating tablets and a preparation method thereof belong to an orally disintegrating traditional Chinese medicine preparation containing easily sublimable medicinal ingredients and a preparation technology thereof. It solves the problem that in the current production and storage of quick-acting heart-relief medicines, the active ingredient-borneol is easy to sublimate, making the content of the medicine unstable, coma, and inconvenient for severe patients to take medicine. The present invention applies modern encapsulation technology, prepares borneol into solid microcapsules (balls) or dispersions, mixes with Rhizoma Chuanxiong and correctives, then mixes with fillers, disintegrants, lubricants, glidants, sieves, Tablets are compressed to produce orally disintegrating tablets. The preparation is convenient to take and can be fully disintegrated without water in the oral cavity. The disintegration time is completed within 10 to 50 seconds, and it can release the drug instantaneously and efficiently, with fast onset and early peak. Therefore, the orally disintegrating tablet is It is especially suitable for some patients with dysphagia or coma, and its curative effect is remarkable. The invention not only has a simple and convenient preparation process, but also optimizes the production environment, and has both economic benefits and social benefits.
Description
Technical field
The invention belongs to a kind of Chinese patent medicine mouth and collapse type preparation and preparation method, relate to a kind of fast-acting heart disease curing oral cavity disintegration tablet that the drug effect stable content contains Borneolum Syntheticum medicine carrying microcapsule or solid dispersion medicine carrying microgranule and preparation method thereof that makes; Be particularly related to and have coronary blood flow increasing, allevating angina pectoris, cure mainly coronary heart disease, uncomfortable in chest, feel suffocated, precordialgia, taking convenience, rapid-action to indication, fast-acting heart disease curing oral cavity disintegration tablet and preparation method thereof.
Background technology
SUXIAO JIUXIN WAN is a kind of Chinese patent medicine of classics, effect such as have calmness, ease pain, resist myocardial ischemia.Be used for coronary heart disease, uncomfortable in chest, feel suffocated, treatment of conditions such as precordialgia.But traditional pill often has absorption not exclusively, has shortcomings such as slow curative effect, and takes inconvenience for the stupor critically ill patient.As fast-acting heart disease curing drop pill, containing needs about 5 minutes, and onset is slow, influences first aid.Though liquid preparation has been avoided containing process, it is not easy to store and carry, and to dysphagia person, often easily medicinal liquid is choked into trachea.
Oral cavity disintegration tablet (orally disiuteg rating tablet) is the novel form of developing in recent years.Compare this dosage form with conventional tablet and need not water and also need not to chew, medicine places on the tongue, and meeting saliva can rapid disintegrate, borrows the swallowing act onset.Also can put the Sublingual, medicine passes through the mucosa absorption onset after the disintegrate rapidly.Current many Western medicine are made oral cavity disintegration tablet, and effect is fine, but traditional Chinese medicine mouth disintegrating tablet there be limited evidence currently of particularly to Chinese medicine volatile, the distillation composition, is not seen the report of making oral cavity disintegration tablet as yet on the market.
Existing commercially available fast-acting heart disease curing preparation also exists drug effect content problem of unstable.Its reason is the main component Borneolum Syntheticum of this medicine, and easily distillation institute extremely.Borneolum Syntheticum as the medicine of having one's ideas straightened out, plays the effect of " fragrance is walked to scurry, and priming is up " in the fast-acting heart disease curing medicament in homeland pharmacy, be to alleviate one of main component uncomfortable in chest.Because this medicine exists the physical property of easy distillation, cause it to have many difficult problems all the time in the routine production of China's Chinese formulated products with in storing; As since the distillation of Borneolum Syntheticum make its in production technology for the content that guarantees it have to high limit feed intake, not only waste herb resource but also make production environment abominable, the workman is difficult to stand; Because the Borneolum Syntheticum distillation causes effective content constantly to run off in patent medicine, unstable before the deadline to messenger drug with content, through accelerated test and keep sample see bright some the annual before the deadline Borneolum Syntheticum composition distillation of the Chinese patent medicine number of dropouts that contains Borneolum Syntheticum of verification unexpectedly can be up to 30% about, be one of technical barrier of the current obstacle modernization of Chinese medicine; The medicinal content standard of stable and controllable has for want of limited it and has obtained the international market access smoothly again; Because Borneolum Syntheticum distils and causes a lot of difficulties to the preparation packing that contains Borneolum Syntheticum, outward appearance, often, the Borneolum Syntheticum sublimate returns goods because of polluting as the transparent plastic packaging of modern patent medicine " bubble eye " packing.Above problem needs to be resolved hurrily.The novel form of developing this medicine is imperative.
In sum, adopting modern medicinal agents technology and novel medicinal auxiliary material, seek to be suitable for parcel drug delivery technologies volatile, the distillation medicine, is the key of the modernization of Chinese medicine; Preparation fast-acting heart disease curing novel form-oral cavity disintegration tablet is the task of top priority.
Summary of the invention
The problem that solves:
At above-mentioned situation, easily distil in order to solve Borneolum Syntheticum, cause SUXIAO JIUXIN WAN drug effect content instability and stupor, critically ill patient are taken inconvenient problem.A kind of modernization parcel drug delivery technologies is provided and take conveniently, rapid-action to indication, reach the peak early, fast-acting heart disease curing oral cavity disintegration tablet evident in efficacy.Thereby for this medicine has increased novel form.
Technical scheme:
Fast-acting heart disease curing oral cavity disintegration tablet, medicinal ingredient are Rhizoma Chuanxiong and Borneolum Syntheticum, and its each composition pharmaceutical dosage is according to the common dose of ministry standard WS3-B-3484-98 regulation, and the quality of two flavor Chinese medicines is 40%～60% than Rhizoma Chuanxiong, and Borneolum Syntheticum is 60%～40%.
The oral cavity disintegration tablet prescription is by weight percentage:
Medicinal ingredient 3.8～18.9%
Filler 48.0～71.0%
Disintegrating agent 9.0～27.8%
Correctives 0.5～1.1%
Lubricant 0.9～2.1%
Fluidizer 0.9～2.1%
Need to prove:
The volatile oil that the form of being used as medicine of medicinal ingredient Rhizoma Chuanxiong is that the water of this medical material is carried, alcohol extraction, ether are carried, a kind of method in the supercritical extraction, vapor extraction method obtains, or parcel medicine carrying microcapsule, the microsphere of volatile oil, or the direct ground product of medical material, the form of being used as medicine of medicinal ingredient Borneolum Syntheticum is its solid dispersion, parcel medicine carrying microcapsule, microsphere.
Borneolum Syntheticum is that fast-acting heart disease curing is alleviated one of main component uncomfortable in chest.Pharmacy procedure of the present invention is made Borneolum Syntheticum solid dispersion or is wrapped up medicine carrying microcapsule, microsphere, runs off in order to the distillation of restriction Borneolum Syntheticum.Because of Borneolum Syntheticum has been dispersed on the solid dispersion soluble in water, has improved this water-fast medicine of Borneolum Syntheticum and in water, dissolved and dispersibility again.
Above-mentioned filler is selected from one or both in microcrystalline Cellulose, dextrin, lactose, starch or the mannitol.
Disintegrating agent is selected from one or both in low substituent group hydroxypropyl methylcellulose (L-HPC), crospolyvinylpyrrolidone (PVPP), crosslinked carboxymethyl fecula sodium (CCMS-Na) or the cross-linking sodium carboxymethyl cellulose (CMC-Na).
Above-mentioned solid dispersion carrier is selected from Polyethylene Glycol, and (being PEG-6000, PEG-4000, PEG-12000, PEG-60000), polyvinylpyrrolidone (are PVP-K
15, K
30, K
60, K
90) and beta-schardinger dextrin-and derivant thereof in one or both.
Correctives is selected from one or both in Mentholum, Oleum menthae, stevioside or the aspartame.
Lubricant is selected from one or both in magnesium stearate, Stepanol MG, the Pulvis Talci.
Fluidizer is selected from one or both in micropowder silica gel, the Pulvis Talci.
The concrete steps of oral cavity disintegration tablet preparation are as follows:
(1) selection of medicinal ingredient and pretreatment
The selection of medicinal ingredient:
The volatile oil that the form of being used as medicine of medicinal ingredient Rhizoma Chuanxiong is that the water of this medical material is carried, alcohol extraction, ether are carried, a kind of method in the supercritical extraction, vapor extraction method obtains, or parcel medicine carrying microcapsule, the microsphere of volatile oil, or the direct ground product of medical material.
The form of being used as medicine of medicinal ingredient Borneolum Syntheticum is its solid dispersion, parcel medicine carrying microcapsule, microsphere.
The pretreatment of medicinal ingredient:
The volatile oil of above-mentioned medical material, the ground product of medical material are all by the pharmacopeia predetermined processing.
The preparation method of above-mentioned parcel medicine carrying microcapsule or microsphere is:
Adopt coacervation or interfacial polymerization; Medicinal ingredient and capsule material are dissolved in the pharmacopeia regulation can be used in the organic solvent of pharmacy, form organic facies; Water intaking in addition, the surfactant of adding 2～3% disperses, and forms water; Water is fully stirred or ultrasound condition under, organic facies is at the uniform velocity splashed into aqueous phase, under the cross-linking agent effect, carry out crosslinked and solidify, obtain medicinal parcel medicine carrying microcapsule or microsphere; The water extraction organic solvent that reuse is excessive, just can obtain discharging medicinal ingredient, runny parcel medicine carrying microcapsule or microsphere powder.Above-mentioned stirring or ultrasonic time 0.5～2 hour; Be not less than 2 hours crosslinked and hardening time.It is pointed out that above-mentionedly in preparation parcel medicine carrying microcapsule, capsule material concentration is 1～10% in the organic facies.
Wherein the capsule material is selected from natural and the synthetic high polymer pharmaceutic adjuvant, and natural polymer medical adjuvant comprises gelatin, arabic gum, sodium alginate, cellulose and cellulosic derivant, chitosan; The synthetic high polymer pharmaceutic adjuvant comprises the copolymer of poly-methyl-prop diluted acid, polymethyl acrylate, poly-methyl-prop diluted acid and poly-methyl-prop diluted acid ester, Youteqi E-100, Youteqi EPO, polyvinyl alcohol, the 1-3 kind in polyvinylpyrrolidone and the Polyethylene Glycol.Organic solvent is selected from the organic solvent of approval usefulness in the pharmacopeia, as ethanol, ethyl acetate, Ethyl formate and chloroform.Surfactant is selected from tween, class of department, sodium lauryl sulphate, polyvinyl alcohol; Polyvinylpyrrolidone, Polyethylene Glycol.Plasticizer such as citric acid, triethyl citrate, Polyethylene Glycol, cross-linking agent such as formaldehyde and glutaraldehyde.
Rhizoma Chuanxiong is handled through said method, promptly obtains drug loading and be 60～90% solid Rhizoma Chuanxiong microcapsule or microsphere, and its particle diameter is 1～100um;
Borneolum Syntheticum is handled through said method, promptly obtains drug loading and be 50～30% Borneolum Syntheticum medicine carrying microcapsule, microsphere or solid dispersion microparticle, and its particle diameter is 1～100um;
(2) film-making
All mixed tabletting:
Medicinal ingredient and correctives pulverize separately are crossed 80 mesh sieves, take by weighing respectively by above-mentioned formula ratio, mix homogeneously, in addition filler, disintegrating agent, fluidizer, lubricant are crossed 80 mesh sieves respectively, by formula ratio take by weighing respectively, mix homogeneously, all mix with the ingredient that is mixed with correctives again, sieve, tabletting; Tabletting adopts conventional tablet pharmaceutical equipment and pressing process can make oral cavity disintegration tablet.
Beneficial effect:
The invention provides a kind of modernized drug delivery technologies of easy distillation Chinese medicine and a kind of taking convenience, the fast-acting heart disease curing oral cavity disintegration tablet rapid-action, evident in efficacy to indication.It uses modern solid dispersion technology and novel medicinal auxiliary material, utilizes the strongly hydrophilic carrier, increases the dissolubility and the dissolution rate of insoluble medicine, improves bioavailability of medicament.Use technique for packing and Rhizoma Chuanxiong and Borneolum Syntheticum can be prepared into solid parcel medicine carrying microcapsule, microsphere or dispersion, to guarantee that oral cavity disintegration tablet is in the loss that can not distil of the lay up period Borneolum Syntheticum of medicine, effective ingredient has rhythm and pace of moving things ground to discharge, and guarantees pharmaceutical effectiveness and the stable content of storage period; Solved currently in producing and storing, effective ingredient-Borneolum Syntheticums such as SUXIAO JIUXIN WAN easily distil, the drug effect content problem of unstable of bringing.Synergism by parcel medicine carrying dispersion technology and disintegrating agent, reach drug oral after, need be not moisture in the oral cavity, just fully disintegrate.The preparation disintegration time can be finished in 10～50 seconds, and did not have sand type.Drug effect is fast, reach the peak early, have no side effect, avirulence, be the old man or swallowed the ideal administering mode of impaired patients.It can promptly alleviate uncomfortable in chest, distressed, is convenient to coronary heart disease patient's first aid and prevention; Thereby solved stupor, critically ill patient and taken inconvenience, the slow problem of onset, and utilized carrier can also cover the bad smell of medicine.The present invention has not only increased novel form for traditional fast-acting heart disease curing medicine, and its preparation method is simple and direct, preparation process resistance is little, use conventional tablet pharmaceutical equipment, i.e. directly compressible production.In addition,, optimized production environment, improved drug quality, both had an economic benefit, social benefit has been arranged again owing to controlled the easily problem of distillation of Borneolum Syntheticum.
Below in conjunction with specific embodiment, the present invention will be further described.Its specific embodiments only is construed as to illustrating, but not any way limits the scope of the invention.
The specific embodiment
Embodiment 1:
The selection of medicinal ingredient and pretreatment
Get 1 kilogram of Rhizoma Chuanxiong, ethanol 10 rises up in the retort, heats back gold-plating, extracts 10 hours, concentrating under reduced pressure reclaims ethanol and volatile oil, merges volatile oil and concentrate.Get above-mentioned volatile oil 10g, join among the alcoholic solution 50g that contains the strange E-100 of 6% You Te, make oil phase.Other 1000ml that fetches water adds Polyethylene Glycol 30g and disperses, and forms water; Water is being carried out under the stirring condition organic facies is at the uniform velocity splashed into aqueous phase, obtaining medicinal Rhizoma Chuanxiong parcel medicine carrying microcapsule through crosslinked, curing; The excessive water 1000ml of reuse extracts organic solvent, more after filtration, drying, obtains discharging medicinal ingredient, runny parcel Rhizoma Chuanxiong medicine carrying microcapsule.Drug loading is 80% solid Rhizoma Chuanxiong microcapsule or microsphere, and its particle diameter is 1～100um.
Get Borneolum Syntheticum 10g, be dissolved in the 50ml ethanol, add polyvinylpyrrolidone and each 0.5g of ethyl cellulose, form oil phase, other 1000ml that fetches water adds 30g sodium lauryl sulphate and 0.5g Polyethylene Glycol, disperses the formation water; Water is being carried out under the stirring condition organic facies is at the uniform velocity splashed into aqueous phase, obtaining medicinal Borneolum Syntheticum parcel medicine carrying microcapsule through crosslinked, curing; With excessive water extraction organic solvent, more after filtration, drying, obtain to discharge medicinal ingredient, runny parcel Borneolum Syntheticum medicine carrying microcapsule.
The Chinese medicine Borneolum Syntheticum is handled through said method, promptly obtains drug loading and be 30% Borneolum Syntheticum medicine carrying microcapsule, and its particle diameter is 1～100um.
Film-making
Prescription (by weight) component is:
Medicinal ingredient medicine carrying Rhizoma Chuanxiong 4.40g
Medicine carrying Borneolum Syntheticum 5.60g
Microcrystalline Cellulose 14.6g
Mannitol 22g
Cross-linking sodium carboxymethyl cellulose 12.00g
Aspartame 0.15g
Herba Menthae 0.15g
Magnesium stearate 0.55g
Micropowder silica gel 0.55g
It makes 1000
Concrete preparation method is:
Cross 80 mesh sieves with giving first medicine carrying Rhizoma Chuanxiong for preparing and Borneolum Syntheticum medicinal ingredient and aspartame, Herba Menthae pulverize separately, mix homogeneously takes by weighing cross-linking sodium carboxymethyl cellulose, microcrystalline Cellulose, mannitol, micropowder silica gel, magnesium stearate again and crosses 80 mesh sieves respectively.Take by weighing respectively by recipe quantity, mix homogeneously mixes with the medicinal ingredient that is mixed with correctives aspartame, Herba Menthae, crosses 80 mesh sieves respectively, uses conventional tablet pharmaceutical equipment and pressing process tabletting, can make oral cavity disintegration tablet.This oral cavity disintegration tablet disintegration in 37 ℃ of aqueous mediums is 20～30 seconds.
Embodiment 2:
The selection of medicinal ingredient and pretreatment and film-maker send out with embodiment 1.
Film-making prescription (by weight) component is:
Medicinal ingredient medicine carrying Rhizoma Chuanxiong 4.40g
Medicine carrying Borneolum Syntheticum 5.60g
Microcrystalline Cellulose 19.0g
Mannitol 14.4g
Carboxymethyl starch sodium 15.0g
Herba Menthae 0.25g
Stevioside 0.05g
Magnesium stearate 0.65g
Micropowder silica gel 0.65g
Make 1000 altogether
Film-making: concrete preparation method is:
With stevioside, Herba Menthae and medicine carrying Rhizoma Chuanxiong, Borneolum Syntheticum, pulverize separately, mix homogeneously is crossed 80 mesh sieves.Press recipe quantity and in addition carboxymethyl starch sodium, microcrystalline Cellulose, mannitol, micropowder silica gel, magnesium stearate crossed 80 mesh sieves respectively, mix homogeneously, again be mixed with stevioside and mix, sieve with the medicinal ingredient of Herba Menthae, tabletting makes oral cavity disintegration tablet.This oral cavity disintegration tablet disintegration in 37 ℃ of water is 20～30 seconds.
Embodiment 3:
The selection of medicinal ingredient and pretreatment and film-maker send out with embodiment 1.
Prescription (by weight) component is:
Medicinal ingredient medicine carrying Rhizoma Chuanxiong 4.40g
Medicine carrying Borneolum Syntheticum 5.60g
Microcrystalline Cellulose 21.00g
Mannitol 15.60g
Crospolyvinylpyrrolidone 12.00g
Stevioside 0.05g
Herba Menthae 0.25g
Magnesium stearate 0.55g
Micropowder silica gel 0.55g
Make 1000 altogether
Concrete preparation method is:
With stevioside and medicine carrying Rhizoma Chuanxiong, Borneolum Syntheticum pulverize separately, cross 80 mesh sieves, take by weighing mix homogeneously by recipe quantity.With cross-linked pvp, microcrystalline Cellulose, mannitol, micropowder silica gel, magnesium stearate are crossed 80 mesh sieves respectively, take by weighing mix homogeneously by recipe quantity in addition.With the medicinal ingredient that the is mixed with stevioside mix homogeneously that sieves, tabletting promptly gets oral cavity disintegration tablet again, and this oral cavity disintegration tablet disintegration in 37 ℃ of aqueous mediums is 40～50 seconds.
Embodiment 4:
The selection of medicinal ingredient and pretreatment:
Get 1 kilogram of Rhizoma Chuanxiong, ethanol 10 rises up in the retort, heats back gold-plating, extracts 10 hours, concentrating under reduced pressure reclaims ethanol and volatile oil, merges volatile oil and concentrate.Get above-mentioned volatile oil 10g, join and contain 4% gelatin, among the water-soluble 40ml of 4% arabic gum, add fine little plain stirring of 1g ethoxy again it is fully mixed, form organic facies.Other 1000ml that fetches water adds the 30g Polyethylene Glycol, disperses, and forms water; Under to water stirring or ultrasound condition, organic facies at the uniform velocity is added drop-wise to aqueous phase, add 20% formaldehyde and 50% glutaraldehyde 5ml again, adjusting pH value to 8～9 are crosslinked, curing obtained medicinal Rhizoma Chuanxiong parcel medicine carrying microcapsule in 2 hours; Again after filtration, drying, obtain discharging medicinal ingredient, runny parcel Rhizoma Chuanxiong medicine carrying microcapsule.
Get Borneolum Syntheticum 10g, be dissolved in the 50ml ethanol, add 3g polyvinylpyrrolidone and 1g ethyl cellulose, form oil phase, other 1000ml that fetches water adds the sodium lauryl sulphate and the Polyethylene Glycol of 10g of 10g, disperses the formation water; Water is being carried out under the stirring condition organic facies is at the uniform velocity splashed into aqueous phase, obtaining medicinal Borneolum Syntheticum parcel medicine carrying microcapsule through crosslinked, curing; The water extraction organic solvent that reuse is excessive more after filtration, drying, obtains discharging medicinal ingredient, runny parcel Borneolum Syntheticum medicine carrying microcapsule.
Film-making: prescription (by weight) component is:
Medicinal ingredient medicine carrying Rhizoma Chuanxiong 4.40g
Medicine carrying Borneolum Syntheticum 5.60g
Lactose 10.7g
Starch 24.2g
Crospolyvinylpyrrolidone 13.7g
Aspartame 0.15g
Herba Menthae 0.15g
Stepanol MG 0.55g
Micropowder silica gel 0.55g
It makes 1000
Concrete preparation method is:
Cross 80 mesh sieves, mix homogeneously with giving first medicine carrying Rhizoma Chuanxiong for preparing and Borneolum Syntheticum medicinal ingredient and aspartame, Herba Menthae pulverize separately; Take by weighing crospolyvinylpyrrolidone, lactose, starch, micropowder silica gel, Stepanol MG again, cross 80 mesh sieves respectively.Take by weighing respectively by recipe quantity, mix homogeneously mixes with the medicinal ingredient that is mixed with correctives aspartame, Herba Menthae, crosses 80 mesh sieves respectively, uses conventional tablet pharmaceutical equipment and pressing process tabletting, can make oral cavity disintegration tablet.This oral cavity disintegration tablet is in 37 ℃ of aqueous mediums, and be 20～30 seconds disintegration.
Embodiment 5:
The selection of medicinal ingredient and pretreatment and film-maker send out with embodiment 1.
Film-making prescription (by weight) component is:
Medicinal ingredient medicine carrying Rhizoma Chuanxiong 6g
Medicine carrying Borneolum Syntheticum 4g
Dextrin 20g
Lactose 13.4g
Carboxymethyl starch sodium 15.0g
Herba Menthae 0.25g
Stevioside 0.05g
Magnesium stearate 0.65g
Micropowder silica gel 0.65g
Make 1000 altogether
Cross 80 mesh sieves, mix homogeneously with giving first medicine carrying Rhizoma Chuanxiong for preparing and Borneolum Syntheticum medicinal ingredient and stevioside, Herba Menthae pulverize separately; Take by weighing carboxymethyl starch sodium, lactose, dextrin, micropowder silica gel, magnesium stearate again, cross 80 mesh sieves respectively.Take by weighing respectively by recipe quantity, mix homogeneously mixes with the medicinal ingredient that is mixed with correctives stevioside, Herba Menthae, crosses 80 mesh sieves respectively, uses conventional tablet pharmaceutical equipment and pressing process tabletting, can make oral cavity disintegration tablet.This sheet disintegration in 37 ℃ of aqueous mediums is 30～40 seconds.
Embodiment 6:
The selection of medicinal ingredient and pretreatment and film-maker send out with embodiment 1.
Its film-making prescription (by weight) component is:
Medicinal ingredient medicine carrying Rhizoma Chuanxiong 4.4g
Borneolum Syntheticum 5.6g
Microcrystalline Cellulose 21g
Mannitol 15g
Crospolyvinylpyrrolidone 11.4g
Stevioside 0.15g
Herba Menthae 0.25g
Magnesium stearate 1.1g
Pulvis Talci 1.1g
Cross 80 mesh sieves, mix homogeneously with giving first medicine carrying Rhizoma Chuanxiong for preparing and Borneolum Syntheticum medicinal ingredient and stevioside, Herba Menthae pulverize separately; Take by weighing crospolyvinylpyrrolidone, microcrystalline Cellulose, mannitol, Pulvis Talci and magnesium stearate again, cross 80 mesh sieves respectively.Take by weighing respectively by recipe quantity, mix homogeneously mixes with the medicinal ingredient that is mixed with flavoring stevioside and Herba Menthae, crosses 80 mesh sieves respectively, uses conventional tablet pharmaceutical equipment and pressing process tabletting, can make oral cavity disintegration tablet.This sheet disintegration in 37 ℃ of aqueous mediums is 30～40 seconds.
Claims (10)
1. fast-acting heart disease curing oral cavity disintegration tablet, medicinal ingredient is Chinese medicine Rhizoma Chuanxiong, Borneolum Syntheticum, its pharmaceutical dosage is by ministry standard WS
3The common dose of-B-3484-98 regulation, the mass ratio of two flavor Chinese medicines is a Rhizoma Chuanxiong 40%～60%, Borneolum Syntheticum is 60%～40%, it is characterized in that, this fast-acting heart disease curing oral cavity disintegration tablet is in mentioned component and ratio uniform mixing, crosses 80 mesh sieves, as the medicinal ingredient of oral cavity disintegration tablet, with the correctives uniform mixing, the homogeneous mixture with filler, disintegrating agent, lubricant, fluidizer all mixes, sieves again, tabletting makes;
The oral cavity disintegration tablet prescription is by weight percentage:
Medicinal ingredient 3.8～18.9%
Filler 48.0～71.0%
Disintegrating agent 9.0～27.8%
Correctives 0.5～1.1%
Lubricant 0.9～2.1%
Fluidizer 0.9～2.1%
2. according to the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, it is characterized in that, the form of being used as medicine of medicinal ingredient Rhizoma Chuanxiong is that the water of this medical material is carried, alcohol extraction, ether are carried, a kind of method in the supercritical extraction, vapor extraction method, the volatile oil that obtains, or parcel medicine carrying microcapsule, the microsphere of volatile oil, or the solid ground product of medical material; The form of being used as medicine of medicinal ingredient Borneolum Syntheticum is solid dispersion, parcel medicine carrying microcapsule, the microsphere of Borneolum Syntheticum.
3. according to the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, it is characterized in that filler is selected from one or both in microcrystalline Cellulose, dextrin, lactose, starch or the mannitol.
4. according to right 1 described fast-acting heart disease curing oral cavity disintegration tablet, it is characterized in that disintegrating agent is selected from one or both in low substituent group hydroxypropyl methylcellulose (L-HPC), crospolyvinylpyrrolidone (PVPP), crosslinked carboxymethyl fecula sodium (CCMS-Na) or the cross-linking sodium carboxymethyl cellulose (CMC-Na).
5. according to the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, it is characterized in that the solid dispersion carrier is selected from Polyethylene Glycol, promptly PEG-6000, PEG-4000, PEG-12000, PEG-60000, polyvinylpyrrolidone are PVP-K
15, PVP-K
30, PVP-K
60, PVP-K
90With in beta-schardinger dextrin-and the derivant thereof one or both.
6. according to the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, it is characterized in that correctives is selected from one or both in Mentholum, Oleum menthae, stevioside or the aspartame.
7. according to the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, it is characterized in that in lubricant such as magnesium stearate, Stepanol MG, the Pulvis Talci one or both.
8. according to the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, it is characterized in that fluidizer is selected from one or both in micropowder silica gel, the Pulvis Talci.
9. the preparation method of the described fast-acting heart disease curing oral cavity disintegration tablet of claim 1, medicinal ingredient is Rhizoma Chuanxiong, Borneolum Syntheticum, its pharmaceutical dosage is by ministry standard WS
3The common dose of-B-3484-98 regulation, the ratio of two flavor Chinese medicines is a Rhizoma Chuanxiong 40%～60%, Borneolum Syntheticum is 60%～40%, it is characterized in that the fast-acting heart disease curing oral cavity disintegration tablet is in mentioned component and ratio uniform mixing, cross 80 mesh sieves, as the medicinal active ingredient of oral cavity disintegration tablet, mix with correctives, filler, disintegrating agent, lubricant, fluidizer respectively, sieve, tabletting makes;
The oral cavity disintegration tablet prescription is by weight percentage:
Medicinal ingredient 3.8～18.9%
Filler 48.0～71.0%
Disintegrating agent 9.0～27.8%
Correctives 0.5～1.1%
Lubricant 0.9～2.1%
Fluidizer 0.9～2.1%
The concrete steps of oral cavity disintegration tablet preparation are as follows:
(1) selection of medicinal ingredient and pretreatment
The selection of medicinal ingredient:
The volatile oil that the form of being used as medicine of medicinal ingredient Rhizoma Chuanxiong is that the water of this medical material is carried, alcohol extraction, ether are carried, a kind of method in the supercritical extraction, vapor extraction method obtains, or parcel medicine carrying microcapsule, the microsphere of this volatile oil, or the direct ground product of medical material; The form of being used as medicine of medicinal ingredient Borneolum Syntheticum is solid dispersion, parcel medicine carrying microcapsule, the microsphere of Borneolum Syntheticum.
The pretreatment of medicinal ingredient:
The volatile oil of above-mentioned medical material, the ground product of medical material are all handled by the conventional method of pharmacopeia regulation.
The preparation method of parcel medicine carrying microcapsule or microsphere is:
Adopt coacervation or interfacial polymerization, medicinal ingredient and capsule material are dissolved in the pharmacopeia regulation, can be used in the organic solvent of pharmacy the formation organic facies; Water intaking adds 2～3% surfactant in addition, disperses, and forms water; Under to water stirring or ultrasound condition, organic facies at the uniform velocity is added drop-wise to aqueous phase, make its dispersion, add plasticizer or cross-linking agent or regulate pH value to 4～10, carry out crosslinked and curing, obtain medicinal parcel medicine carrying microcapsule or microsphere; With excessive water extraction organic solvent, more after filtration, drying, obtain discharging medicinal ingredient, runny parcel medicine carrying microcapsule or microsphere; Stirring or ultrasonic time 0.5～2 hour; Be not less than 2 hours crosslinked and hardening time.
Wherein the capsule material is selected from natural and the synthetic high polymer pharmaceutic adjuvant, and natural polymer medical adjuvant comprises gelatin, arabic gum, sodium alginate, cellulose and cellulosic derivant, chitosan; The synthetic high polymer pharmaceutic adjuvant comprises the copolymer of poly-methyl-prop diluted acid, polymethyl acrylate, poly-methyl-prop diluted acid and poly-methyl-prop diluted acid ester, Youteqi E-100, Youteqi EPO, polyvinyl alcohol, the 1-3 kind in polyvinylpyrrolidone and the Polyethylene Glycol.Organic solvent is selected from the organic solvent of approval usefulness in the pharmacopeia, as ethanol, ethyl acetate, Ethyl formate and chloroform.Surfactant is selected from tween, class of department, sodium lauryl sulphate, polyvinyl alcohol, polyvinylpyrrolidone, Polyethylene Glycol.Plasticizer is selected from citric acid, triethyl citrate, Polyethylene Glycol, and cross-linking agent is selected from formaldehyde and glutaraldehyde.Above-mentioned stirring or ultrasonic time are 0.5～2 hour; Be not less than 2 hours crosslinked and hardening time.
The Chinese medicine Rhizoma Chuanxiong is handled through said method, promptly obtains drug loading and be 60%～90% solid Rhizoma Chuanxiong microcapsule or microsphere, and its particle diameter is 1～100um;
The Chinese medicine Borneolum Syntheticum is handled through said method, promptly obtains drug loading and be 50～30% Borneolum Syntheticum medicine carrying microcapsule or solid dispersion medicine carrying microgranule, and its particle diameter is 1～100um;
(2) film-making
Medicinal ingredient and correctives pulverize separately are crossed 80 mesh sieves, take by weighing respectively by above-mentioned formula ratio, mix homogeneously, in addition filler, disintegrating agent, fluidizer, lubricant are crossed 80 mesh sieves respectively, by formula ratio take by weighing respectively, mix homogeneously, all mix with the ingredient that is mixed with correctives again, sieve, tabletting; Tabletting adopts conventional tablet pharmaceutical equipment and pressing process can make oral cavity disintegration tablet.
10. according to the preparation method of the described fast-acting heart disease curing oral cavity disintegration tablet of claim 9, it is characterized in that capsule material concentration is 1～10% in the organic facies in preparation parcel medicine carrying microcapsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410019985 CN1273115C (en) | 2004-07-15 | 2004-07-15 | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410019985 CN1273115C (en) | 2004-07-15 | 2004-07-15 | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593505A true CN1593505A (en) | 2005-03-16 |
| CN1273115C CN1273115C (en) | 2006-09-06 |
Family
ID=34663139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410019985 Expired - Fee Related CN1273115C (en) | 2004-07-15 | 2004-07-15 | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1273115C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362320A (en) * | 2015-12-02 | 2016-03-02 | 广东药学院 | Method of preparing quick-acting jiuxin orally disintegrating tablet through 3D printing |
| CN109044990A (en) * | 2018-08-02 | 2018-12-21 | 合肥中科力科技有限公司 | A kind of drug package preparation process |
-
2004
- 2004-07-15 CN CN 200410019985 patent/CN1273115C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362320A (en) * | 2015-12-02 | 2016-03-02 | 广东药学院 | Method of preparing quick-acting jiuxin orally disintegrating tablet through 3D printing |
| CN105362320B (en) * | 2015-12-02 | 2019-06-07 | 广东药科大学 | A kind of method that 3D printing prepares fast-acting heart disease curing oral disnitegration tablet |
| CN109044990A (en) * | 2018-08-02 | 2018-12-21 | 合肥中科力科技有限公司 | A kind of drug package preparation process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1273115C (en) | 2006-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1135103C (en) | Controlled release of drugs delivered by sublingual or buccal administration | |
| CN1029770C (en) | Process for the preparation of controlled-release oral medicaments | |
| CN1822819A (en) | Oral controlled release forms useful for reducing or preventing nicotine cravings | |
| CN1211078C (en) | Regulated release preparations | |
| CN1031183A (en) | Dihydropyridine storage formulations | |
| CN1863517A (en) | Rapidly disintegrating formulation | |
| CN101073563A (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN1593505A (en) | Quick acting and heart resurrecting oral disintegrating tablet and its preparation process | |
| CN1265785C (en) | Chrono-slow-releasing prepn. hydrochloride verapamil | |
| CN1543943A (en) | Oral silymarin sustained-release preparation and preparation method thereof | |
| CN1270712C (en) | Felodipine controlled-release preparation | |
| CN1443535A (en) | Tegasevod maleate oral preparation and its preparation process-for curing intestinal irritability syndrome | |
| CN1899268A (en) | L-amlodipine besilate dripping pill and its preparing method | |
| CN1303990C (en) | Sodium ferulate oral disintegrating tablet and its preparation process | |
| CN1234361C (en) | Method for preparing medicine of levo-stephandinine | |
| CN1931166A (en) | medications for high blood pressure | |
| CN1297263C (en) | Calcium gluconate oral disintegrating tablet and its preparation process | |
| CN1861056A (en) | Slow-releasing prepn. contg. gastrodin | |
| CN1634096A (en) | Notoginseng total saponin orally disintegrating tablet | |
| CN1250208C (en) | Fluoxetine enteric coated tablet | |
| CN1513439A (en) | Slow release medicine of pseudo-ephedrine hydrochloride | |
| CN1165311C (en) | Slow-releasing composition of estrogen medicine and its preparing process | |
| CN1628654A (en) | Liver benefiting effective agent prepared from hepadestal and preparation method thereof | |
| CN1726916A (en) | Oral disintegration tablet for dropping blood sugar and preparation method | |
| CN1309376C (en) | Musk slow-controlled release preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060906 Termination date: 20120715 |